Recent Notable Insider Transactions for Penny Stocks: Muscle Maker, RocketFuel Blockchain, and VBI Vaccines


  • 10% owner Aggia FZ LLC acquired 8,855,452 shares at an average price of $3.12, totaling around $27.63 million.
  • CEO Peter M. Jensen purchased 1,000 shares at an average price of $0.19, spending around $185.
  • Director Steven Gillis acquired 609,090 shares at an average price of $1.65, with a total cost of approximately $1 million.

The Dow Jones ended Tuesday on a positive note, rising more than 300 points, indicating an optimistic market sentiment. For investors and traders focusing on penny stocks, insider transactions can offer valuable insights into a company’s potential. Notably, Muscle Maker (GRIL) saw 10% owner Aggia FZ LLC acquire a substantial 8,855,452 shares at an average price of $3.12, totaling approximately $27.63 million. Alongside this transaction, Muscle Maker made amendments to its current Services Agreement with AGGIA LLC FZ. The company operates several healthier-for-you restaurant concepts, including Muscle Maker Grill restaurants, SuperFit Foods meal prep, and Pokemoto Hawaiian Poke restaurants.

RocketFuel Blockchain (RKFL) also witnessed insider activity, with CEO Peter M. Jensen purchasing 1,000 shares at an average price of $0.19, amounting to about $185. This coincided with RocketFuel’s collaboration announcement with Poncho Brotherz, a leading family-owned and operated farm-to-retail cannabis retail store. As a development-stage company, RocketFuel Blockchain Inc is focused on creating blockchain-based check-out systems that aim to improve speed, security, and user-friendliness.

Meanwhile, VBI Vaccines (VBIV) saw Director Steven Gillis acquire 609,090 shares at an average price of $1.65, costing around $1 million. This transaction occurred alongside VBI Vaccines’ announcement of an $18 million public offering and a $3 million concurrent registered direct offering. VBI Vaccines Inc is a commercial-stage biopharmaceutical company based in the US, specializing in developing next-generation vaccines to address unmet needs in infectious diseases and immuno-oncology.

Copyright © 2023 InvestingSalary. All rights reserved. IS does not provide any investment advice.

Investing Salary provides free access to quality, truthful news for everyone, believing that information should be equally accessible. We hope that this will enable more people to stay informed about current events, understand their effects, and be motivated to take action.

If you feel that we have helped you get the right market knowledge please consider supporting us through Patreon. Even a single dollar counts.

Related news


Subscribe To Our Newsletter

Receive the latest market insights